RUNX1-dependent mechanisms in biological control and dysregulation in cancer
Authors
Hong, DeliFritz, Andrew J.
Gordon, Jonathan A.
Tye, Coralee E.
Boyd, Joseph R.
Tracy, Kirsten M.
Frietze, Seth E.
Carr, Frances E.
Nickerson, Jeffrey A.
Van Wijnen, Andre J.
Imbalzano, Anthony N.
Zaidi, Sayyed K.
Lian, Jane B.
Stein, Janet L.
Stein, Gary S.
UMass Chan Affiliations
Nickerson LabImbalzano Lab
Department of Pediatrics
Department of Biochemistry and Molecular Pharmacology
Document Type
Journal ArticlePublication Date
2019-06-01Keywords
RUNX1breast cancer
cancer
hematopoiesis
leukemia
mammary gland development
Amino Acids, Peptides, and Proteins
Cancer Biology
Cell Biology
Cells
Cellular and Molecular Physiology
Developmental Biology
Neoplasms
Metadata
Show full item recordAbstract
The RUNX1 transcription factor has recently been shown to be obligatory for normal development. RUNX1 controls the expression of genes essential for proper development in many cell lineages and tissues including blood, bone, cartilage, hair follicles, and mammary glands. Compromised RUNX1 regulation is associated with many cancers. In this review, we highlight evidence for RUNX1 control in both invertebrate and mammalian development and recent novel findings of perturbed RUNX1 control in breast cancer that has implications for other solid tumors. As RUNX1 is essential for definitive hematopoiesis, RUNX1 mutations in hematopoietic lineage cells have been implicated in the etiology of several leukemias. Studies of solid tumors have revealed a context-dependent function for RUNX1 either as an oncogene or a tumor suppressor. These RUNX1 functions have been reported for breast, prostate, lung, and skin cancers that are related to cancer subtypes and different stages of tumor development. Growing evidence suggests that RUNX1 suppresses aggressiveness in most breast cancer subtypes particularly in the early stage of tumorigenesis. Several studies have identified RUNX1 suppression of the breast cancer epithelial-to-mesenchymal transition. Most recently, RUNX1 repression of cancer stem cells and tumorsphere formation was reported for breast cancer. It is anticipated that these new discoveries of the context-dependent diversity of RUNX1 functions will lead to innovative therapeutic strategies for the intervention of cancer and other abnormalities of normal tissues.Source
J Cell Physiol. 2019 Jun;234(6):8597-8609. doi: 10.1002/jcp.27841. Epub 2018 Dec 4. Link to article on publisher's site
DOI
10.1002/jcp.27841Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29408PubMed ID
30515788Related Resources
ae974a485f413a2113503eed53cd6c53
10.1002/jcp.27841